伊立替康联合氟尿嘧啶治疗晚期直肠癌  

Clinical Observation On The CPT-11 Plus 5-FU For treatment Advanced Rectal Cancer

作　　者：唐卫军 邹洪元 彭春芳 

机构地区：[1]重庆市江津区中心医院肿瘤科,重庆市402260

出　　处：《中国基层医药》2011年第2期161-162,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的评价伊立替康（CPT-11）联合氟尿嘧啶（5-FU）治疗晚期直肠癌的临床疗效及毒副作用。方法选择晚期直肠癌患者86例，根据给药方式的不同将患者随机分为FOLFIRI治疗组和IFL治疗组。通过CR、PR、SD及RR等指标观察临床疗效，通过骨髓抑制、消化道反应及静脉炎等指标观察毒副作用。结果FOLFIRI治疗组和IFL治疗组在CR、PR、SD及RR等临床疗效方面差异无统计学意义（均P〉0．05），在骨髓抑制、消化道反应及静脉炎等毒副作用方面差异也无统计学意义（均P〉0．05）。结论伊立替康联合5-FU治疗晚期直肠癌疗效较好，毒副作用较少。Objective To evaluate the efficacy and adverse events of irinotecan（ CPT-11 ） combined with 5- FU in treatment of patients with advanced rectal cancer. Methods 86 patients were randomly divided into FOLFIRI treatment group and IFL treatment group. The efficacy and adverse events were observed. Results There was no statistically significant difference between FOLFIRI treatment group and IFL treatment group in CR.PR.SD and RR（ all P 〉 0.05 ）. There was also no statistically significant difference between FOLFIRI treatment group and IFL treatment group in adverse events （ all P 〉 0.05 ）. Conclusion Irinotecan in combination with 5-FU was effective and had some tolerable adverse events in treating patients with advanced rectal cancer in both FOLFIRI treatment group and IFL treatment group.

关 键 词：直肠肿瘤 伊立替康 氟尿嘧啶 化学治疗 

分 类 号：R735[医药卫生—肿瘤]